Trial Profile

A Multicenter, Open-label, Phase Ib/II Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Penpulimab (Primary)
Indications Solid tumours
Focus Therapeutic Use
Sponsors Akeso Biopharma

Most Recent Events

11 Oct 2022 Status changed from recruiting to completed.
26 Sep 2022 Results (n=67) assessing safety and anti-tumor activity of penpulimab in patients with advanced upper gastrointestinal cancers, published in the Cancer Immunology Immunotherapy.
22 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com